Search in:

Advanced search

Expert Opinion on Pharmacotherapy Volume 10, 2009 - Issue 3

Submit an article Journal homepage

574

Views

CrossRef citations to date

Altmetric

Review

Pharmacotherapy of helminth infection

Erwin van den Enden Institute of Tropical Medicine, Kronenburgstraat 43/3, 2000 Antwerp, Belgium +32 3 247 64 27; +32 3 247 64 52; [email protected]

, MD

Pages 435-451 | Published online: 04 Feb 2009

Cite this article
https://doi.org/10.1517/14656560902722463

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Renoux G. The general immunopharmacology of levamisole. Drugs 1980;20:89-99
PubMed Web of Science ®Google Scholar
Albonico M, Bickle Q, Ramsan M, et al. Efficacy of mebendazole and levamisole alone or in combination against intestinal nematode infections after repeated targeted mebendazole treatment in Zanzibar. Bull World Health Organ 2003;81:343-52
PubMed Web of Science ®Google Scholar
Grover JK, Vats V, Uppal G, Yadav S. Anthelmintics: a review. Trop Gastroenterol 2001;22:180-9
PubMedGoogle Scholar
Keiser J, Utzinger J. Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. JAMA 2008;299:1937-48
PubMed Web of Science ®Google Scholar
Albonico M, Bickle Q, Haji HJ, et al. Evaluation of the efficacy of pyrantel-oxantel for the treatment of soil-transmitted nematode infections. Trans R Soc Trop Med Hyg 2002;96:685-90
PubMed Web of Science ®Google Scholar
St Georgiev V. Chemotherapy of enterobiasis (oxyuriasis). Expert Opin Pharmacother 2001;2:267-75
PubMedGoogle Scholar
Reynoldson JA, Behnke JM, Pallant LJ, et al. Failure of pyrantel in treatment of human hookworm infections (Ancylostoma duodenale) in the Kimberley region of north west Australia. Acta Trop 1997;68:301-12
PubMed Web of Science ®Google Scholar
Krepel HP, Haring T, Baeta S, Polderman AM. Treatment of mixed Oesophagostomum and hookworm infection: effect of albendazole, pyrantel pamoate, levamisole and thiabendazole. Trans R Soc Trop Med Hyg 1993;87:87-9
PubMed Web of Science ®Google Scholar
Bloom A. Studies of the mode of action of metrifonate and DDVP in schistosomes – cholinesterase activity and the hepatic shift. Acta Pharmacol Toxicol (Copenh) 1981;49(Suppl 5):109-13
PubMedGoogle Scholar
O'Leary KA, Tracy JW. Schistosoma mansoni: glutathione S-transferase-catalyzed detoxication of dichlorvos. Exp Parasitol 1991;72:355-61
PubMed Web of Science ®Google Scholar
Danso-Appiah A, Utzinger J, Liu J, Olliaro P. Drugs for treating urinary schistosomiasis. Cochrane Database Syst Rev 2008;16(3):CD000053
Google Scholar
Bassiouny HK, Soliman NK, el Daly SM, Badr NM. Human fascioliasis in Egypt: effect of infection and efficacy of bithionol treatment. J Trop Med Hyg 1991;94:333-7
PubMed Web of Science ®Google Scholar
Mavrova AT, Anichina KK, Vuchev DI, et al. Antihelminthic activity of some newly synthesized 5(6)-(un)substituted- 1H-benzimidazol-2-ylthioacetylpiperazine derivatives. Eur J Med Chem 2006;41:1412-20
PubMed Web of Science ®Google Scholar
Martin RJ, Robertson AP, Bjorn H. Target sites of anthelmintics. Parasitology 1997;114(Suppl):S111-24
PubMed Web of Science ®Google Scholar
Ross AG, Bartley PB, Sleigh AC, et al. Schistosomiasis. N Engl J Med 2002;346:1212-20
PubMed Web of Science ®Google Scholar
Cioli D, Pica-Mattoccia L, Archer S. Drug resistance in schistosomes. Parasitol Today 1993;9:162-6
PubMedGoogle Scholar
Craig P, Ito A. Intestinal cestodes. Curr Opin Infect Dis 2007;20:524-32
PubMed Web of Science ®Google Scholar
Varma TK, Shinghal TN, Saxena M, Ahluwalia SS. Studies on the comparative efficacy of mebendazole, flubendazole and niclosamide against human tapeworm infections. Indian J Public Health 1990;34:163-8
PubMedGoogle Scholar
Wulff C, Haeberlein S, Haas W. Cream formulations protecting against cercarial dermatitis by Trichobilharzia. Parasitol Res 2007;101:91-7
PubMed Web of Science ®Google Scholar
McMahon JE. A comparative trial of praziquantel, metrifonate and niridazole against Schistosoma haematobium. Ann Trop Med Parasitol 1983;77:139-42
PubMed Web of Science ®Google Scholar
El Beheiry AH, Kamel MN, Gad A. Niridazole and fertility in bilharzial men. Arch Androl 1982;8:297-300
PubMedGoogle Scholar
Lacey E. Mode of action of benzimidazoles. Parasitol Today 1990;6:112-5
PubMedGoogle Scholar
Hodgkinson JE, Clark HJ, Kaplan RM, et al. The role of polymorphisms at beta tubulin isotype 1 codons 167 and 200 in benzimidazole resistance in cyathostomins. Int J Parasitol 2008;38:1149-60
PubMed Web of Science ®Google Scholar
Bethony J, Brooker S, Albonico M, et al. Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. Lancet 2006;367:1521-32
PubMed Web of Science ®Google Scholar
Bhargava A, Jukes M, Lambo J, et al. Anthelmintic treatment improves the hemoglobin and serum ferritin concentrations of Tanzanian schoolchildren. Food Nutr Bull 2003;24:332-42
PubMedGoogle Scholar
Stephenson LS, Latham MC, Kurz KM, et al. Treatment with a single dose of albendazole improves growth of Kenyan schoolchildren with hookworm, Trichuris trichiura, and Ascaris lumbricoides infections. Am J Trop Med Hyg 1989;41:78-87
PubMed Web of Science ®Google Scholar
de Silva NR. Impact of mass chemotherapy on the morbidity due to soil-transmitted nematodes. Acta Trop 2003;86:197-214
PubMed Web of Science ®Google Scholar
Beasley NM, Tomkins AM, Hall A, et al. The impact of population level deworming on the haemoglobin levels of schoolchildren in Tanga, Tanzania. Trop Med Int Health 1999;4:744-50
PubMed Web of Science ®Google Scholar
Gyorkos TW, Larocque R, Casapia M, Gotuzzo E. Lack of risk of adverse birth outcomes after deworming in pregnant women. Pediatr Infect Dis J 2006;25:791-4
PubMed Web of Science ®Google Scholar
de Silva NR, Sirisena JL, Gunasekera DP, et al. Effect of mebendazole therapy during pregnancy on birth outcome. Lancet 1999;353:1145-9
PubMed Web of Science ®Google Scholar
Bradley M, Horton J. Assessing the risk of benzimidazole therapy during pregnancy. Trans R Soc Trop Med Hyg 2001;95:72-3
PubMed Web of Science ®Google Scholar
Montresor A, Awasthi S, Crompton DW. Use of benzimidazoles in children younger than 24 months for the treatment of soil-transmitted helminthiasis. Acta Trop 2003;86:223-32
PubMed Web of Science ®Google Scholar
Grove DI. Treatment of strongyloidiasis with thiabendazole: an analysis of toxicity and effectiveness. Trans R Soc Trop Med Hyg 1982;76:114-8
PubMed Web of Science ®Google Scholar
Dayan AD. Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Trop 2003;86:141-59
PubMed Web of Science ®Google Scholar
Nontasut P, Singhasivanon V, Prarinyanuparp V, et al. Effect of single-dose albendazole and single-dose mebendazole on Necator americanus. Southeast Asian J Trop Med Public Health 1989;20:237-42
PubMedGoogle Scholar
Wilmshurst JM, Robb SA. Can mebendazole cause lateralized occipital seizures? Eur J Paediatr Neurol 1998;2:323-4
PubMedGoogle Scholar
Lange H, Eggers R, Bircher J. Increased systemic availability of albendazole when taken with a fatty meal. Eur J Clin Pharmacol 1988;34:315-7
PubMed Web of Science ®Google Scholar
Marriner SE, Morris DL, Dickson B, Bogan JA. Pharmacokinetics of albendazole in man. Eur J Clin Pharmacol 1986;30:705-8
PubMed Web of Science ®Google Scholar
Redondo PA, Alvarez AI, Garcia JL, et al. Presystemic metabolism of albendazole: experimental evidence of an efflux process of albendazole sulfoxide to intestinal lumen. Drug Metab Dispos 1999;27:736-40
PubMed Web of Science ®Google Scholar
Morris DL, Chinnery JB, Georgiou G, et al. Penetration of albendazole sulphoxide into hydatid cysts. Gut 1987;28:75-80
PubMed Web of Science ®Google Scholar
Moskopp D, Lotterer E. Concentrations of albendazole in serum, cerebrospinal fluid and hydatidous brain cyst. Neurosurg Rev 1993;16:35-7
PubMed Web of Science ®Google Scholar
Venkatesan P. Albendazole. J Antimicrob Chemother 1998;41:145-7
PubMed Web of Science ®Google Scholar
Schipper HG, Koopmans RP, Nagy J, et al. Effect of dose increase or cimetidine co-administration on albendazole bioavailability. Am J Trop Med Hyg 2000;63:270-3
PubMed Web of Science ®Google Scholar
Takayanagui OM, Lanchote VL, Marques MP, Bonato PS. Therapy for neurocysticercosis: pharmacokinetic interaction of albendazole sulfoxide with dexamethasone. Ther Drug Monit 1997;19:51-5
PubMed Web of Science ®Google Scholar
Sacko M, De Clercq D, Behnke JM, et al. Comparison of the efficacy of mebendazole, albendazole and pyrantel in treatment of human hookworm infections in the southern region of Mali, West Africa. Trans R Soc Trop Med Hyg 1999;93:195-203
PubMed Web of Science ®Google Scholar
Heukelbach J, Feldmeier H. Epidemiological and clinical characteristics of hookworm-related cutaneous larva migrans. Lancet Infect Dis 2008;8:302-9
PubMed Web of Science ®Google Scholar
Hochedez P, Caumes E. Hookworm-related cutaneous larva migrans. J Travel Med 2007;14:326-33
PubMed Web of Science ®Google Scholar
Menard A, Dos SG, Dekumyoy P, et al. Imported cutaneous gnathostomiasis: report of five cases. Trans R Soc Trop Med Hyg 2003;97:200-2
PubMed Web of Science ®Google Scholar
Archibald LK, Beeching NJ, Gill GV, et al. Albendazole is effective treatment for chronic strongyloidiasis. QJM 1993;86:191-5
PubMedGoogle Scholar
Suputtamongkol Y, Kungpanichkul N, Silpasakorn S, Beeching NJ. Efficacy and safety of a single-dose veterinary preparation of ivermectin versus 7-day high-dose albendazole for chronic strongyloidiasis. Int J Antimicrob Agents 2008;31:46-9
PubMed Web of Science ®Google Scholar
Datry A, Hilmarsdottir I, Mayorga-Sagastume R, et al. Treatment of Strongyloides stercoralis infection with ivermectin compared with albendazole: results of an open study of 60 cases. Trans R Soc Trop Med Hyg 1994;88:344-5
PubMed Web of Science ®Google Scholar
Saporito L, Scarlata F, Colomba C, et al. Human toxocariasis: a report of nine cases. Acta Paediatr 2008;97:1301-2
PubMed Web of Science ®Google Scholar
Nabi F, Palaha HK, Sekhsaria D, Chiatale A. Capillaria hepatica infestation. Indian Pediatr 2007;44:781-2
PubMed Web of Science ®Google Scholar
Cross JH, Basaca-Sevilla V. Albendazole in the treatment of intestinal capillariasis. Southeast Asian J Trop Med Public Health 1987;18:507-10
PubMedGoogle Scholar
Kraivichian P, Kulkumthorn M, Yingyourd P, et al. Albendazole for the treatment of human gnathostomiasis. Trans R Soc Trop Med Hyg 1992;86:418-21
PubMed Web of Science ®Google Scholar
Nontasut P, Claesson BA, Dekumyoy P, et al. Double-dose ivermectin vs albendazole for the treatment of gnathostomiasis. Southeast Asian J Trop Med Public Health 2005;36:650-2
PubMedGoogle Scholar
Liu YH, Wang XG, Gao P, Qian MX. Experimental and clinical trial of albendazole in the treatment of Clonorchiasis sinensis. Chin Med J (Engl) 1991;104:27-31
PubMed Web of Science ®Google Scholar
McKellar QA, Scott EW. The benzimidazole anthelmintic agents- a review. J Vet Pharmacol Ther 1990;13:223-47
PubMed Web of Science ®Google Scholar
Akkoc N, Kuruuzum Z, Akar S, et al. A large-scale outbreak of trichinellosis caused by Trichinella britovi in Turkey. Zoonoses Public Health. In press
Google Scholar
Schellenberg RS, Tan BJ, Irvine JD, et al. An outbreak of trichinellosis due to consumption of bear meat infected with Trichinella nativa, in 2 northern Saskatchewan communities. J Infect Dis 2003;188:835-43
PubMed Web of Science ®Google Scholar
Jongwutiwes S, Chantachum N, Kraivichian P, et al. First outbreak of human trichinellosis caused by Trichinella pseudospiralis. Clin Infect Dis 1998;26:111-5
PubMed Web of Science ®Google Scholar
Andrews JR, Ainsworth R, Abernethy D. Trichinella pseudospiralis in humans: description of a case and its treatment. Trans R Soc Trop Med Hyg 1994;88:200-3
PubMed Web of Science ®Google Scholar
Singh SP, Panda C, Rout N, Mishra AP. Anal albendazole application for pruritus ani in threadworm infestation. J Trop Pediatr 2005;51:386
PubMed Web of Science ®Google Scholar
Smego RA Jr, Bhatti S, Khaliq AA, Beg MA. Percutaneous aspiration-injection-reaspiration drainage plus albendazole or mebendazole for hepatic cystic echinococcosis: a meta-analysis. Clin Infect Dis 2003;37:1073-83
PubMed Web of Science ®Google Scholar
Smego RA Jr, Sebanego P. Treatment options for hepatic cystic echinococcosis. Int J Infect Dis 2005;9:69-76
PubMed Web of Science ®Google Scholar
Caglar R, Yuzbasioglu MF, Bulbuloglu E, et al. In vitro effectiveness of different chemical agents on scolices of hydatid cyst. J Invest Surg 2008;21:71-5
PubMed Web of Science ®Google Scholar
Gil-Grande LA, Rodriguez-Caabeiro F, Prieto JG, et al. Randomised controlled trial of efficacy of albendazole in intra-abdominal hydatid disease. Lancet 1993;342:1269-72
PubMed Web of Science ®Google Scholar
Wen H, New RR, Craig PS. Diagnosis and treatment of human hydatidosis. Br J Clin Pharmacol 1993;35:565-74
PubMed Web of Science ®Google Scholar
Ntusi NA, Horsfall C. Severe disseminated hydatid disease successfully treated medically with prolonged administration of albendazole. QJM 2008;101:745-6
PubMed Web of Science ®Google Scholar
Aggarwal P, Wali JP. Albendazole in the treatment of pulmonary echinococcosis. Thorax 1991;46:599-600
PubMed Web of Science ®Google Scholar
Nahmias J, Goldsmith R, Soibelman M, et al. Three- to 7-year follow-up after albendazole treatment of 68 patients with cystic echinococcosis (hydatid disease). Ann Trop Med Parasitol 1994;88:295-304
PubMed Web of Science ®Google Scholar
Wilson JF, Rausch RL, McMahon BJ, Schantz PM. Parasiticidal effect of chemotherapy in alveolar hydatid disease: review of experience with mebendazole and albendazole in Alaskan Eskimos. Clin Infect Dis 1992;15:234-49
PubMed Web of Science ®Google Scholar
Ammann RW, Ilitsch N, Marincek B, Freiburghaus AU. Effect of chemotherapy on the larval mass and the long-term course of alveolar echinococcosis. Swiss Echinococcosis Study Group. Hepatology 1994;19:735-42
PubMed Web of Science ®Google Scholar
Wen H, Zou PF, Yang WG, et al. Albendazole chemotherapy for human cystic and alveolar echinococcosis in north-western China. Trans R Soc Trop Med Hyg 1994;88:340-3
PubMed Web of Science ®Google Scholar
Garcia HH, Evans CA, Nash TE, et al. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev 2002;15:747-56
PubMed Web of Science ®Google Scholar
Carpio A, Kelvin EA, Bagiella E, et al. Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry 2008;79:1050-5
PubMed Web of Science ®Google Scholar
Garg RK. Treatment of neurocysticercosis: is it beneficial? Expert Rev Anti Infect Ther 2008;6:435-40
PubMed Web of Science ®Google Scholar
Matthaiou DK, Panos G, Adamidi ES, Falagas ME. Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials. PLoS Negl Trop Dis 2008;2(3):e194
PubMed Web of Science ®Google Scholar
Garcia HH. Antiparasitic drugs in neurocysticercosis: albendazole or praziquantel? Expert Rev Anti Infect Ther 2008;6:295-8
PubMed Web of Science ®Google Scholar
Gyapong JO, Kumaraswami V, Biswas G, Ottesen EA. Treatment strategies underpinning the global programme to eliminate lymphatic filariasis. Expert Opin Pharmacother 2005;6:179-200
PubMed Web of Science ®Google Scholar
Ottesen EA, Ismail MM, Horton J. The role of albendazole in programmes to eliminate lymphatic filariasis. Parasitol Today 1999;15:382-6
PubMedGoogle Scholar
Addiss DG, Beach MJ, Streit TG, et al. Randomised placebo-controlled comparison of ivermectin and albendazole alone and in combination for Wuchereria bancrofti microfilaraemia in Haitian children. Lancet 1997;350:480-4
PubMed Web of Science ®Google Scholar
Beach MJ, Streit TG, Addiss DG, et al. Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian schoolchildren. Am J Trop Med Hyg 1999;60:479-86
PubMed Web of Science ®Google Scholar
Critchley J, Addiss D, Gamble C, et al. International Filariasis Review Group. Albendazole for lymphatic filariasis. Cochrane Database Syst Rev 2005;19:CD003753
Google Scholar
Klion AD, Horton J, Nutman TB. Albendazole therapy for loiasis refractory to diethylcarbamazine treatment. Clin Infect Dis 1999;29:680-2
PubMed Web of Science ®Google Scholar
Horton J. Albendazole: a review of anthelmintic efficacy and safety in humans. Parasitology 2000;121(Suppl):S113-32
PubMed Web of Science ®Google Scholar
Bagheri H, Simiand E, Montastruc JL, Magnaval JF. Adverse drug reactions to anthelmintics. Ann Pharmacother 2004;38:383-8
PubMed Web of Science ®Google Scholar
Lecaillon JB, Godbillon J, Campestrini J, et al. Effect of food on the bioavailability of triclabendazole in patients with fascioliasis. Br J Clin Pharmacol 1998;45:601-4
PubMed Web of Science ®Google Scholar
El Tantawy WH, Salem HF, Mohammed Safwat NA. Effect of fascioliasis on the pharmacokinetic parameters of triclabendazole in human subjects. Pharm World Sci 2007;29:190-8
PubMedGoogle Scholar
Keiser J, El Ela NA, El Komy E, et al. Triclabendazole and its two main metabolites lack activity against Schistosoma mansoni in the mouse model. Am J Trop Med Hyg 2006;75:287-91
PubMed Web of Science ®Google Scholar
Marcos LA, Terashima A, Dupont HL, Gotuzzo E. Strongyloides hyperinfection syndrome: an emerging global infectious disease. Trans R Soc Trop Med Hyg 2008;102:314-8
PubMed Web of Science ®Google Scholar
Brennan GP, Fairweather I, Trudgett A, et al. Understanding triclabendazole resistance. Exp Mol Pathol 2007;82:104-9
PubMed Web of Science ®Google Scholar
Aksoy DY, Kerimoglu U, Oto A, et al. Infection with Fasciola hepatica. Clin Microbiol Infect 2005;11:859-61
PubMed Web of Science ®Google Scholar
Jave OJA, Alban OM, Sagastegui PC, Soriano YS. Treatment of human hepatic fasciolaisis with triclabendazole [Article in Spanish]. Rev Gastroenterol Peru 1999;19:216-20
PubMedGoogle Scholar
Fairweather I. Triclabendazole: new skills to unravel an old(ish) enigma. J Helminthol 2005;79:227-34
PubMed Web of Science ®Google Scholar
Mottier L, Alvarez L, Fairweather I, Lanusse C. Resistance-induced changes in triclabendazole transport in Fasciola hepatica: ivermectin reversal effect. J Parasitol 2006;92:1355-60
PubMed Web of Science ®Google Scholar
Calvopina M, Guderian RH, Paredes W, et al. Treatment of human pulmonary paragonimiasis with triclabendazole: clinical tolerance and drug efficacy. Trans R Soc Trop Med Hyg 1998;92:566-9
PubMed Web of Science ®Google Scholar
Keiser J, Engels D, Büscher G, Utzinger J. Triclabendazole for the treatment of fascioliasis and paragonimiasis. Expert Opin Investig Drugs 2005;14:1513-26
PubMed Web of Science ®Google Scholar
Gao J, Liu Y, Wang X, Hu P. Triclabendazole in the treatment of Paragonimiasis skrjabini. Chin Med J (Engl) 2003;116:1683-6
PubMed Web of Science ®Google Scholar
el Morshedy H, Farghaly A, Sharaf S, et al. Triclabendazole in the treatment of human fascioliasis: a community-based study. East Mediterr Health J 1999;5:888-94
PubMedGoogle Scholar
Adinarayanan S, Critchley J, Das PK, Gelband H. Diethylcarbamazine (DEC)-medicated salt for community-based control of lymphatic filariasis. Cochrane Database Syst Rev 2007;CD003758
Google Scholar
Awadzi K, Adjepon-Yamoah KK, Edwards G, et al. The effect of moderate urine alkalinisation on low dose diethylcarbamazine therapy in patients with onchocerciasis. Br J Clin Pharmacol 1986;21:669-76
PubMed Web of Science ®Google Scholar
Peixoto CA, Rocha A, Aguiar-Santos A, Florencio MS. The effects of diethylcarbamazine on the ultrastructure of microfilariae of Wuchereria bancrofti in vivo and in vitro. Parasitol Res 2004;92:513-7
PubMed Web of Science ®Google Scholar
Tisch DJ, Michael E, Kazura JW. Mass chemotherapy options to control lymphatic filariasis: a systematic review. Lancet Infect Dis 2005;5:514-23
PubMed Web of Science ®Google Scholar
Keiser PB, Reynolds SM, Awadzi K, et al. Bacterial endosymbionts of Onchocerca volvulus in the pathogenesis of posttreatment reactions. J Infect Dis 2002;185:805-11
PubMed Web of Science ®Google Scholar
Cross HF, Haarbrink M, Egerton G, et al. Severe reactions to filarial chemotherapy and release of Wolbachia endosymbionts into blood. Lancet 2001;358:1873-5
PubMed Web of Science ®Google Scholar
Dreyer G, Addiss D, Noroes J. Does longevity of adult Wuchereria bancrofti increase with decreasing intensity of parasite transmission? Insights from clinical observations. Trans R Soc Trop Med Hyg 2005;99:883-92
PubMed Web of Science ®Google Scholar
Carme B, Boulesteix J, Boutes H, Puruehnce MF. Five cases of encephalitis during treatment of loiasis with diethylcarbamazine. Am J Trop Med Hyg 1991;44:684-90
PubMed Web of Science ®Google Scholar
Bouree P, Duedari N, Bisaro F, Norol F. Value of filariopheresis in the treatment of Loa loa filariasis. Pathol Biol (Paris) 1993;41:410-4
PubMedGoogle Scholar
Pawlowski Z. Toxocariasis in humans: clinical expression and treatment dilemma. J Helminthol 2001;75:299-305
PubMed Web of Science ®Google Scholar
Finsterer J, Auer H. Neurotoxocarosis. Rev Inst Med Trop Sao Paulo 2007;49:279-87
PubMedGoogle Scholar
Omura S. Ivermectin: 25 years and still going strong. Int J Antimicrob Agents 2008;31:91-8
PubMed Web of Science ®Google Scholar
Omura S, Crump A. The life and times of ivermectin – a success story. Nat Rev Microbiol 2004;2:984-9
PubMed Web of Science ®Google Scholar
Ikeda T. Pharmacological effects of ivermectin, an antiparasitic agent for intestinal strongyloidiasis: its mode of action and clinical efficacy. Nippon Yakurigaku Zasshi 2003;122:527-38
PubMedGoogle Scholar
Zeng Z, Andrew NW, Arison BH, et al. Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes. Xenobiotica 1998;28:313-21
PubMed Web of Science ®Google Scholar
Basanez MG, Pion SD, Boakes E, et al. Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis. Lancet Infect Dis 2008;8:310-22
PubMed Web of Science ®Google Scholar
Thylefors B, Alleman MM, Twum-Danso NA. Operational lessons from 20 years of the Mectizan Donation Program for the control of onchocerciasis. Trop Med Int Health 2008;13:689-96
PubMed Web of Science ®Google Scholar
Martin-Prevel Y, Cosnefroy JY, Tshipamba P, et al. Tolerance and efficacy of single high-dose ivermectin for the treatment of loiasis. Am J Trop Med Hyg 1993;48:186-92
PubMed Web of Science ®Google Scholar
Twum-Danso NA. Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future. Filaria J 2003;2(Suppl 1):S7
PubMedGoogle Scholar
Nutman TB, Nash TE, Ottesen EA. Ivermectin in the successful treatment of a patient with Mansonella ozzardi infection. J Infect Dis 1987;156:662-5
PubMed Web of Science ®Google Scholar
Van den Enden E, Van Gompel A, Van der SP, et al. Treatment failure of a single high dose of ivermectin for Mansonella perstans filariasis. Trans R Soc Trop Med Hyg 1993;87:90
PubMed Web of Science ®Google Scholar
Naquira C, Jimenez G, Guerra JG, et al. Ivermectin for human strongyloidiasis and other intestinal helminths. Am J Trop Med Hyg 1989;40:304-9
PubMed Web of Science ®Google Scholar
Van den Enden E, Stevens A, Van Gompel A. Treatment of cutaneous larva migrans. N Engl J Med 1998;339:1246-7
PubMedGoogle Scholar
Gann PH, Neva FA, Gam AA. A randomized trial of single- and two-dose ivermectin versus thiabendazole for treatment of strongyloidiasis. J Infect Dis 1994;169:1076-9
PubMed Web of Science ®Google Scholar
Zaha O, Hirata T, Kinjo F, et al. Efficacy of ivermectin for chronic strongyloidiasis: two single doses given 2 weeks apart. J Infect Chemother 2002;8:94-8
PubMedGoogle Scholar
Zaha O, Hirata T, Uchima N, et al. Comparison of anthelmintic effects of two doses of ivermectin on intestinal strongyloidiasis in patients negative or positive for anti-HTLV-1 antibody. J Infect Chemother 2004;10:348-51
PubMedGoogle Scholar
Torres JR, Isturiz R, Murillo J, et al. Efficacy of ivermectin in the treatment of strongyloidiasis complicating AIDS. Clin Infect Dis 1993;17:900-2
PubMed Web of Science ®Google Scholar
Kraivichian K, Nuchprayoon S, Sitichalernchai P, et al. Treatment of cutaneous gnathostomiasis with ivermectin. Am J Trop Med Hyg 2004;71:623-8
PubMed Web of Science ®Google Scholar
Tarr PE, Miele PS, Peregoy KS, et al. Case report: Rectal adminstration of ivermectin to a patient with Strongyloides hyperinfection syndrome. Am J Trop Med Hyg 2003;68:453-5
PubMed Web of Science ®Google Scholar
Strong M, Johnstone PW. Interventions for treating scabies. Cochrane Database Syst Rev 2007;CD000320
Google Scholar
Foucault C, Ranque S, Badiaga S, et al. Oral ivermectin in the treatment of body lice. J Infect Dis 2006;193:474-6
PubMed Web of Science ®Google Scholar
Jones KN, English JC III. Review of common therapeutic options in the United States for the treatment of pediculosis capitis. Clin Infect Dis 2003;36:1355-61
PubMed Web of Science ®Google Scholar
Greene BM, Taylor HR, Cupp EW, et al. Comparison of ivermectin and diethylcarbamazine in the treatment of onchocerciasis. N Engl J Med 1985;313:133-8
PubMed Web of Science ®Google Scholar
Pacque M, Munoz B, Poetschke G, et al. Pregnancy outcome after inadvertent ivermectin treatment during community-based distribution. Lancet 1990;336:1486-9
PubMed Web of Science ®Google Scholar
Twum-Danso NA. Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases. Filaria J 2003;2(Suppl 1):S3
PubMedGoogle Scholar
Twum-Danso NA. Mass treatment of onchocerciasis with ivermectin: should people with epilepsy and/or growth-retardation syndromes be excluded? Ann Trop Med Parasitol 2004;98:99-114
PubMed Web of Science ®Google Scholar
Eng JK, Prichard RK. A comparison of genetic polymorphism in populations of Onchocerca volvulus from untreated and ivermectin-treated patients. Mol Biochem Parasitol 2005;142:193-202
PubMed Web of Science ®Google Scholar
Prichard RK, Roulet A. ABC transporters and beta-tubulin in macrocyclic lactone resistance: prospects for marker development. Parasitology 2007;134:1123-32
PubMed Web of Science ®Google Scholar
Awadzi K, Boakye DA, Edwards G, et al. An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol 2004;98:231-49
PubMed Web of Science ®Google Scholar
Osei-Atweneboana MY, Eng JK, Boakye DA, et al. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet 2007;369:2021-9
PubMed Web of Science ®Google Scholar
Sotelo J, Jung H. Pharmacokinetic optimisation of the treatment of neurocysticercosis. Clin Pharmacokinet 1998;34:503-15
PubMed Web of Science ®Google Scholar
Castro N, Gonzalez-Esquivel DF, Lopez M, Jung H. Comparative analysis of the influence of food and cimetidine in plasma levels of praziquantel. Rev Invest Clin 2003;55:655-61
PubMedGoogle Scholar
Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet 2006;368:1106-18
PubMed Web of Science ®Google Scholar
Cioli D, Pica-Mattoccia L. Praziquantel. Parasitol Res 2003;90(Supp 1):S3-9
PubMed Web of Science ®Google Scholar
Bottieau E, Clerinx J, de Vega MR, et al. Imported Katayama fever: clinical and biological features at presentation and during treatment. J Infect 2006;52:339-45
PubMed Web of Science ®Google Scholar
van Lieshout L, Stelma FF, Guisse F, et al. The contribution of host-related factors to low cure rates of praziquantel for the treatment of Schistosoma mansoni in Senegal. Am J Trop Med Hyg 1999;61:760-5
PubMed Web of Science ®Google Scholar
Ismail M, Botros S, Metwally A, et al. Resistance to praziquantel: direct evidence from Schistosoma mansoni isolated from Egyptian villagers. Am J Trop Med Hyg 1999;60:932-5
PubMed Web of Science ®Google Scholar
Tsai MH, Marx KA, Ismail MM, Tao L. Randomly amplified polymorphic DNA (RAPD) polymerase chain reaction assay for identification of Schistosoma mansoni strains sensitive or tolerant to anti-schistosomal drugs. J Parasitol 2000;86:146-9
PubMed Web of Science ®Google Scholar
Kieu TL, Bronshtein AM, Sabgaida TP. [Clonorchiasis in the People's Republic of Vietnam. 2. The clinico-parasitological examination of a focus and a trial of prazinquantel treatment]. Med Parazitol (Mosk) 1992;7-11
PubMedGoogle Scholar
Choi MH, Chang BC, Lee SJ, et al. Therapeutic evaluation of sustained-releasing praziquantel (SRP) for clonorchiasis: phase 1 and 2 clinical studies. Korean J Parasitol 2006;44:361-6
PubMedGoogle Scholar
Keiser J, Utzinger J. Chemotherapy for major food-borne trematodes: a review. Expert Opin Pharmacother 2004;5:1711-26
PubMed Web of Science ®Google Scholar
Pretell EJ, Garcia HH, Gilman RH, et al. Failure of one-day praziquantel treatment in patients with multiple neurocysticercosis lesions. Clin Neurol Neurosurg 2001;103:175-7
PubMed Web of Science ®Google Scholar
Adam I, Elwasila ET, Homeida M. Is praziquantel therapy safe during pregnancy? Trans R Soc Trop Med Hyg 2004;98:540-3
PubMed Web of Science ®Google Scholar
Olds GR. Administration of praziquantel to pregnant and lactating women. Acta Trop 2003;86:185-95
PubMed Web of Science ®Google Scholar
White CA Jr. Nitazoxanide: a new broad spectrum antiparasitic agent. Expert Rev Anti Infect Ther 2004;2:43-9
PubMedGoogle Scholar
Nitazoxanide (Alinia)- new anti-protozoal agent. Med Lett Drugs Ther 2003;45:29-31
PubMed Web of Science ®Google Scholar
Anderson VR, Curran MP. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs 2007;67:1947-67
PubMed Web of Science ®Google Scholar
Hemphill A, Mueller J, Esposito M. Nitazoxanide, a broad-spectrum thiazolide anti-infective agent for the treatment of gastrointestinal infections. Expert Opin Pharmacother 2006;7:953-64
PubMed Web of Science ®Google Scholar
Juan JO, Lopez CN, Gargala G, Favennec L. Comparative clinical studies of nitazoxanide, albendazole and praziquantel in the treatment of ascariasis, trichuriasis and hymenolepiasis in children from Peru. Trans R Soc Trop Med Hyg 2002;96:193-6
PubMed Web of Science ®Google Scholar
Chero JC, Saito M, Bustos JA, et al. Hymenolepis nana infection: symptoms and response to nitazoxanide in field conditions. Trans R Soc Trop Med Hyg 2007;101:203-5
PubMed Web of Science ®Google Scholar
Rossignol JF, Maisonneuve H. Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana infections. Am J Trop Med Hyg 1984;33:511-2
PubMed Web of Science ®Google Scholar
Lateef M, Zargar SA, Khan AR, et al. Successful treatment of niclosamide- and praziquantel-resistant beef tapeworm infection with nitazoxanide. Int J Infect Dis 2008;12:80-2
PubMed Web of Science ®Google Scholar
Palomares-Alonso F, Piliado JC, Palencia G, et al. Efficacy of nitazoxanide, tizoxanide and tizoxanide/albendazole sulphoxide combination against Taenia crassiceps cysts. J Antimicrob Chemother 2007;59:212-8
PubMed Web of Science ®Google Scholar
Reuter S, Manfras B, Merkle M, et al. In vitro activities of itraconazole, methiazole, and nitazoxanide versus Echinococcus multilocularis larvae. Antimicrob Agents Chemother 2006;50:2966-70
PubMed Web of Science ®Google Scholar
Favennec L, Jave OJ, Gargala G, et al. Double-blind, randomized, placebo-controlled study of nitazoxanide in the treatment of fascioliasis in adults and children from northern Peru. Aliment Pharmacol Ther 2003;17:265-70
PubMed Web of Science ®Google Scholar
Taylor MJ, Bandi C, Hoerauf A. Wolbachia bacterial endosymbionts of filarial nematodes. Adv Parasitol 2005;60:245-84
PubMed Web of Science ®Google Scholar
Hoerauf A, Specht S, Buttner M, et al. Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Med Microbiol Immunol 2008;197:295-311
PubMed Web of Science ®Google Scholar
Hoerauf A, Marfo-Debrekyei Y, Buttner M, et al. Effects of 6-week azithromycin treatment on the Wolbachia endobacteria of Onchocerca volvulus. Parasitol Res 2008;103:279-86
PubMed Web of Science ®Google Scholar
Specht S, Mand S, Marfo-Debrekyei Y, et al. Efficacy of 2- and 4-week rifampicin treatment on the Wolbachia of Onchocerca volvulus. Parasitol Res 2008;103:1303-9
PubMed Web of Science ®Google Scholar
Taylor MJ, Makunde WH, McGarry HF, et al. Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. Lancet 2005;365:2116-21
PubMed Web of Science ®Google Scholar
Turner JD, Mand S, Debrah AY, et al. A randomized, double-blind clinical trial of a 3-week course of doxycycline plus albendazole and ivermectin for the treatment of Wuchereria bancrofti infection. Clin Infect Dis 2006;42:1081-9
PubMed Web of Science ®Google Scholar
Xiao S, Tanner M, N'Goran EK, et al. Recent investigations of artemether, a novel agent for the prevention of schistosomiasis japonica, mansoni and haematobia. Acta Trop 2002;82:175-81
PubMed Web of Science ®Google Scholar
Li YS, Chen HG, He HB, et al. A double-blind field trial on the effects of artemether on Schistosoma japonicum infection in a highly endemic focus in southern China. Acta Trop 2005;96:184-90
PubMed Web of Science ®Google Scholar
Adam I, Elhardello OA, Elhadi MO, et al. The antischistosomal efficacies of artesunate-sulfamethoxypyrazine-pyrimethamine and artemether-lumefantrine administered as treatment for uncomplicated, Plasmodium falciparum malaria. Ann Trop Med Parasitol 2008;102:39-44
PubMed Web of Science ®Google Scholar
Boulanger D, Dieng Y, Cisse B, et al. Antischistosomal efficacy of artesunate combination therapies administered as curative treatments for malaria attacks. Trans R Soc Trop Med Hyg 2007;101:113-6
PubMed Web of Science ®Google Scholar
Borrmann S, Szlezák N, Faucher JF, et al. Artesunate and praziquantel for the treatment of Schistosoma haematobium infections: a double-blind, randomized, placebo-controlled study. J Infect Dis 2001;184:1363-6
PubMed Web of Science ®Google Scholar
Utzinger J, Xiao SH, Tanner M, Keiser J. Artemisinins for schistosomiasis and beyond. Curr Opin Investig Drugs 2007;8:105-16
PubMed Web of Science ®Google Scholar
Hien TT, Truong NT, Minh NH, et al. A randomized controlled pilot study of artesunate versus triclabendazole for human fascioliasis in central Vietnam. Am J Trop Med Hyg 2008;78:388-92
PubMed Web of Science ®Google Scholar
Keiser J, Morson G. Fasciola hepatica: tegumental alterations in adult flukes following in vitro and in vivo administration of artesunate and artemether. Exp Parasitol 2008;118:228-37
PubMed Web of Science ®Google Scholar
Xiao SH, Wu HM, Tanner M, et al. Tribendimidine: a promising, safe and broad-spectrum anthelmintic agent from China. Acta Trop 2005;94:1-14
PubMed Web of Science ®Google Scholar
Zhang JH, Xiao SH, Wu ZX, et al. [Tribendimidine enteric coated tablet in treatment of 1,292 cases with intestinal nematode infection- a phase IV clinical trial]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2008;26:6-9
PubMedGoogle Scholar
Keiser J, Xiao SH, Chollet J, et al. Evaluation of the in vivo activity of tribendimidine against Schistosoma mansoni, Fasciola hepatica, Clonorchis sinensis, and Opisthorchis viverrini. Antimicrob Agents Chemother 2007;51:1096-8
PubMed Web of Science ®Google Scholar
Xue J, Utzinger J, Zhang YN, et al. Artemether and tribendimidine lack activity in experimental treatment of Paragonimus westermani in the dog. Parasitol Res 2008;102:537-40
PubMed Web of Science ®Google Scholar
Xiao SH, Jian X, Tanner M, et al. Artemether, artesunate, praziquantel and tribendimidine administered singly at different dosages against Clonorchis sinensis: a comparative in vivo study. Acta Trop 2008;106:54-9
PubMed Web of Science ®Google Scholar
Keiser J, Utzinger J, Xiao SH, et al. Opisthorchis viverrini: efficacy and tegumental alterations following administration of tribendimidine in vivo and in vitro. Parasitol Res 2008;102:771-6
PubMed Web of Science ®Google Scholar
Keiser J, Thiemann K, Endriss Y, Utzinger J. Strongyloides ratti: In Vitro and In Vivo Activity of Tribendimidine. PLoS Negl Trop Dis 2008;2(1):e136
Google Scholar
Steinmann P, Zhou XN, Du ZW, et al. Tribendimine and albendazole for treating soil-transmitted helminths, Strongyloides stercoralis and Taenia spp.: Open-label randomized trial. PLoS Negl Trop Dis 2008;2(10):e322
PubMed Web of Science ®Google Scholar
Sheir Z, Nasr AA, Massoud A, et al. A safe, effective, herbal antischistosomal therapy derived from myrrh. Am J Trop Med Hyg 2001;65:700-4
PubMed Web of Science ®Google Scholar
Barakat R, Elmorshedy H, Fenwick A. Efficacy of myrrh in the treatment of human Schistosomiasis mansoni. Am J Trop Med Hyg 2005;73:365-7
PubMed Web of Science ®Google Scholar
Botros S, Sayed H, El Dusoki H, et al. Efficacy of mirazid in comparison with praziquantel in Egyptian Schistosoma mansoni-infected school children and households. Am J Trop Med Hyg 2005;72:119-23
PubMed Web of Science ®Google Scholar
Abo-Madyan AA, Morsy TA, Motawea SM, Morsy AT. Clinical trial of Mirazid in treatment of human fascioliasis, Ezbet El-Bakly (Tamyia Center) Al-Fayoum Governorate. J Egypt Soc Parasitol 2004;34:807-18
PubMedGoogle Scholar
Harder A, Holden-Dye L, Walker R, Wunderlich F. Mechanisms of action of emodepside. Parasitol Res 2005;97(Suppl 1):S1-S10
PubMed Web of Science ®Google Scholar
Scherkenbeck J, Jeschke P, Harder A. PF1022A and related cyclodepsipeptides – a novel class of anthelmintics. Curr Top Med Chem 2002;2:759-77
PubMedGoogle Scholar
Harder A, Schmitt-Wrede HP, Krucken J, et al. Cyclooctadepsipeptides- an anthelmintically active class of compounds exhibiting a novel mode of action. Int J Antimicrob Agents 2003;22:318-31
PubMed Web of Science ®Google Scholar
Guest M, Bull K, Walker RJ, et al. The calcium-activated potassium channel, SLO-1, is required for the action of the novel cyclo-octadepsipeptide anthelmintic, emodepside, in Caenorhabditis elegans. Int J Parasitol 2007;37:1577-88
PubMed Web of Science ®Google Scholar
Tagboto SK, Townson S. Onchocerca volvulus and O. lienalis: the microfilaricidal activity of moxidectin compared with that of ivermectin in vitro and in vivo. Ann Trop Med Parasitol 1996;90:497-505
PubMed Web of Science ®Google Scholar
Saeger B, Schmitt-Wrede HP, Dehnhardt M, et al. Latrophilin-like receptor from the parasitic nematode Haemonchus contortus as target for the anthelmintic depsipeptide PF1022A. FASEB J 2001;15:1332-4
PubMed Web of Science ®Google Scholar
Mentz MB, Graeff-Teixeira C. Drug trials for treatment of human angiostrongyliasis. Rev Inst Med Trop Sao Paulo 2003;45:179-84
PubMedGoogle Scholar
Cotreau MM, Warren S, Ryan JL, et al. The antiparasitic moxidectin: safety, tolerability, and pharmacokinetics in humans. J Clin Pharmacol 2003;43:1108-15
PubMed Web of Science ®Google Scholar
Keiser J, Xiao SH, Dong Y, et al. Clonorchicidal properties of the synthetic trioxolane OZ78. J Parasitol 2007;93:1208-13
PubMed Web of Science ®Google Scholar
Keiser J, Utzinger J, Vennerstrom JL, et al. Activity of artemether and OZ78 against triclabendazole-resistant Fasciola hepatica. Trans R Soc Trop Med Hyg 2007;101:1219-22
PubMed Web of Science ®Google Scholar
Keiser J, Utzinger J. Food-borne trematodiasis: current chemotherapy and advances with artemisinins and synthetic trioxolanes. Trends Parasitol 2007;23:555-62
PubMed Web of Science ®Google Scholar
Keiser J, Utzinger J. Artemisinins and synthetic trioxolanes in the treatment of helminth infections. Curr Opin Infect Dis 2007;20:605-12
PubMed Web of Science ®Google Scholar
Xiao SH, Keiser J, Chollet J, et al. In vitro and in vivo activities of synthetic trioxolanes against major human schistosome species. Antimicrob Agents Chemother 2007;51:1440-5
PubMed Web of Science ®Google Scholar
Caffrey CR. Chemotherapy of schistosomiasis: present and future. Curr Opin Chem Biol 2007;11:433-9
PubMed Web of Science ®Google Scholar
Omura S, Miyadera H, Ui H, et al. An anthelmintic compound, nafuredin, shows selective inhibition of complex I in helminth mitochondria. Proc Natl Acad Sci USA 2001;98:60-2
PubMed Web of Science ®Google Scholar
Cioli D, Valle C, Angelucci F, Miele AE. Will new antischistosomal drugs finally emerge? Trends Parasitol 2008;24:379-82
PubMed Web of Science ®Google Scholar
Sayed AA, Simeonov A, Thomas CJ, et al. Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat Med 2008;14:407-12
PubMed Web of Science ®Google Scholar
Behm CA, Bendig MM, McCarter JP, Sluder AE. RNAi-based discovery and validation of new drug targets in filarial nematodes. Trends Parasitol 2005;21:97-100
PubMed Web of Science ®Google Scholar
Rey P, Debonne JM. Therapeutic alternatives in case of failure of first-line treatment of intestinal helminthiasis in adults. Med Trop (Mars) 2006;66:324-8
PubMedGoogle Scholar
Lawrence D. What's in a name? Drug resistance in helminth parasites. Lancet Infect Dis 2008;8:536
Web of Science ®Google Scholar
Bennett A, Guyatt H. Reducing intestinal nematode infection: efficacy of albendazole and mebendazole. Parasitol Today 2000;16:71-4
PubMedGoogle Scholar
Waghorn TS, Leathwick DM, Miller CM, Atkinson DS. Brave or gullible: testing the concept that leaving susceptible parasites in refugia will slow the development of anthelmintic resistance. NZ Vet J 2008;56:158-63
PubMed Web of Science ®Google Scholar
Hotez PJ, Bethony JM, Oliveira SC, et al. Multivalent anthelminthic vaccine to prevent hookworm and schistosomiasis. Expert Rev Vaccines 2008;7:745-52
PubMed Web of Science ®Google Scholar
Oliveira SC, Fonseca CT, Cardoso FC, et al. Recent advances in vaccine research against schistosomiasis in Brazil. Acta Trop 2008;108:256-62
PubMed Web of Science ®Google Scholar
Brutus L, Watier L, Hanitrasoamampionona V, et al. Confirmation of the protective effect of Ascaris lumbricoides on Plasmodium falciparum infection: results of a randomized trial in Madagascar. Am J Trop Med Hyg 2007;77:1091-5
PubMed Web of Science ®Google Scholar
Reddy A, Fried B. Atopic disorders and parasitic infections. Adv Parasitol 2008;66:149-91
PubMed Web of Science ®Google Scholar
van Riet E. Protection from skin test reactivity by helminth infections: Trichuris trichiura induces protection in the long term. Clin Exp Allergy 2008;38:1702-4
PubMed Web of Science ®Google Scholar
Ruyssers NE, De Winter BY, De Man JG, et al. Worms and the treatment of inflammatory bowel disease: are molecules the answer? Clin Dev Immunol 2008;2008:567314
PubMedGoogle Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Pharmacotherapy of helminth infection

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Pharmacotherapy of helminth infection

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date